Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C13H18ClF3N2O.ClH |
| Molecular Weight | 347.204 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(=C1)C(F)(F)F
InChI
InChIKey=MMCDXJOMPMIKGP-UHFFFAOYSA-N
InChI=1S/C13H18ClF3N2O.ClH/c1-12(2,3)19-6-10(20)7-4-8(13(15,16)17)11(18)9(14)5-7;/h4-5,10,19-20H,6,18H2,1-3H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C13H18ClF3N2O |
| Molecular Weight | 310.743 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/6152155
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/6152155
Mabuterol is a long acting βeta 2-adrenergic agonist which stimulates adenylyl cyclase activity and the closing of calcium channels. Studies indicate that the R enantiomer of mabuterol is more potent than the S enantiomer. In addition, the half-life is longer in the R enantiomer than the S. Studies conducted on rats and dogs show that mabuterol acts as a bronchodilator. At high concentrations mabuterol can also antagonize beta1 adrenoceptors in guinea pigs
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development and validation of a liquid chromatography tandem mass spectrometry method for the analysis of beta-agonists in animal feed and drinking water. | 2010-09-24 |
|
| [Determination of fifteen beta-agonists in animal urine by high performance liquid chromatography-tandem mass spectrometry]. | 2010-08 |
|
| Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010-04 |
|
| How to decrease ion suppression in a multiresidue determination of beta-agonists in animal liver and urine by liquid chromatography-mass spectrometry with ion-trap detector. | 2009-04-01 |
|
| Validation of radioimmunoassay screening methods for beta-agonists in bovine liver according to Commission Decision 2002/657/EC. | 2008-12 |
|
| Simultaneous enantioseparation of four beta2-agonists by capillary electrophoresis with cyclodextrin additives. Study of the enantioselective mechanism. | 2008-12 |
|
| [Multi-residue analysis of 10 beta2-agonists in animal tissues using gas chromatography-mass spectrometry]. | 2008-01 |
|
| Enantiomeric separation of beta2-agonists on macrocyclic antibiotic chiral stationary phases in high performance liquid chromatography. | 2007-11 |
|
| Application of an enzyme-linked immunosorbent assay for the detection of clenbuterol residues in swine urine and feeds. | 2007-02 |
|
| Enantioselective pharmacokinetics of mabuterol in rats studied using sequential achiral and chiral HPLC. | 2005-11 |
|
| Determination of beta-agonists in liver and retina by liquid chromatography-tandem mass spectrometry. | 2005-03-12 |
|
| Determination of beta-agonist residues in bovine urine using liquid chromatography-tandem mass spectrometry. | 2005-03-12 |
|
| Improvement in steroid screening for doping control with special emphasis on stanozolol. | 2003-01-24 |
|
| Integrated acquisition of analytical and biopharmaceutical screening data for beta-adrenergic-drugs employing diversified macrocycle supported potentiometric detection in HPLC systems. | 2002-08 |
|
| Use of molecularly imprinted polymers in the solid-phase extraction of clenbuterol from animal feeds and biological matrices. | 2001-08-05 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:29:24 GMT 2025
by
admin
on
Mon Mar 31 21:29:24 GMT 2025
|
| Record UNII |
536V290790
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
536V290790
Created by
admin on Mon Mar 31 21:29:24 GMT 2025 , Edited by admin on Mon Mar 31 21:29:24 GMT 2025
|
PRIMARY | |||
|
m6973
Created by
admin on Mon Mar 31 21:29:24 GMT 2025 , Edited by admin on Mon Mar 31 21:29:24 GMT 2025
|
PRIMARY | Merck Index | ||
|
56795-19-8
Created by
admin on Mon Mar 31 21:29:24 GMT 2025 , Edited by admin on Mon Mar 31 21:29:24 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
54240-36-7
Created by
admin on Mon Mar 31 21:29:24 GMT 2025 , Edited by admin on Mon Mar 31 21:29:24 GMT 2025
|
PRIMARY | |||
|
41037
Created by
admin on Mon Mar 31 21:29:24 GMT 2025 , Edited by admin on Mon Mar 31 21:29:24 GMT 2025
|
PRIMARY | |||
|
CHEMBL86749
Created by
admin on Mon Mar 31 21:29:24 GMT 2025 , Edited by admin on Mon Mar 31 21:29:24 GMT 2025
|
PRIMARY | |||
|
SUB35845
Created by
admin on Mon Mar 31 21:29:24 GMT 2025 , Edited by admin on Mon Mar 31 21:29:24 GMT 2025
|
PRIMARY | |||
|
100000128599
Created by
admin on Mon Mar 31 21:29:24 GMT 2025 , Edited by admin on Mon Mar 31 21:29:24 GMT 2025
|
PRIMARY | |||
|
95656-48-7
Created by
admin on Mon Mar 31 21:29:24 GMT 2025 , Edited by admin on Mon Mar 31 21:29:24 GMT 2025
|
SUPERSEDED | |||
|
DTXSID3046798
Created by
admin on Mon Mar 31 21:29:24 GMT 2025 , Edited by admin on Mon Mar 31 21:29:24 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |